Corona Remedies Ltd IPO (Dec 2025) – ₹655.37 Cr Pharma Drama: From Cardio Pills to Capital Thrills! 💊📈
1. At a Glance
Corona Remedies Ltd is marching into Dalal Street with a ₹655.37 crore IPO that’s basically one big “Offer for Sale” (OFS). Translation: existing shareholders are cashing out faster than your friend who says “I’ll pay you back next week.” The IPO opened on December 8, 2025, and closes December 10, 2025, with the listing expected on December 15. The price band is a heart-throbbing ₹1008–₹1062 per share, because why settle for three digits when you can look “premium”?
The market cap before IPO stands tall at around ₹6,495 crore, making it no small fry in the pharma pond. The issue isn’t raising any new money for the company — it’s pure OFS, baby — but that hasn’t stopped the crowd from showing up. As of Day 2, the IPO was 9.9x subscribed, with retail at 6.8x, QIBs at 1.76x, and HNIs going berserk at 28x.
Corona’s revenue for FY25 was a healthy ₹1,202.35 crore (up 18%), and PAT jumped 65% to ₹149.43 crore. With ROE at 27.5%, ROCE at 41.32%, and Debt-to-Equity at a chill 0.10, this pharma player seems fit enough to survive another market variant.
The promoters — Dr. Kirtikumar Mehta, Niravkumar Mehta, and Ankur Mehta — control 72.5% pre-IPO. And after this listing, they’ll still have control… but with a lot more champagne money.
2. Introduction
Every IPO season has that one company that makes you go, “Wait, this isn’t a COVID spin-off?” Yes, Corona Remedies carries that pandemic name baggage, but this Gujarat-based pharma giant was around long before you started sanitizing your doorknob.
Founded in 2004, the company makes and markets medicines across women’s healthcare, cardiology, diabetology, urology, and pain management. In short, they sell everything from “I’m exhausted” tablets to “I can’t afford to faint at work” capsules.
Their two manufacturing units in Gujarat churn out 1,285 million dosage units annually, enough to medicate half the country’s hypochondriacs. They’ve built 71 brands across major therapeutic areas and have 2,671 medical representatives hustling across 22 states, convincing doctors why their pill deserves a prescription.
The company has grown rapidly — from ₹891 crore total income in FY23 to ₹1,202 crore in FY25. Profits too jumped from ₹84.9 crore to ₹149.4 crore. And with EBITDA margins at 20.55%, Corona’s operational health looks better than most smallcaps’ blood pressure.
But here’s the twist: this IPO isn’t about raising funds for expansion — it’s purely a promoter exit. So, while the company’s fundamentals are healthy, the motivation behind the IPO is more “let’s monetize success” than “we need cash to grow.”
3. Business Model – WTF Do They Even Do?
Corona Remedies plays in the Indian branded generics market — a place where competition is tougher than explaining pharma accounting to your parents. They develop, manufacture, and market prescription drugs targeting chronic therapies, especially in mid-income urban and semi-urban markets — the “middle of the pyramid,” as they call it.
Their segments include:
Women’s Healthcare: Pills and syrups that fund at least one diamond purchase per year.
Cardio-Diabeto: Medicines for your dad’s post-biryani regret.
Pain Management: Tablets that make you forget your gym mistakes.
Urology: Because bladder control is underrated.
Multispecialty Range: Vitamins, minerals, gastrointestinal and respiratory aids — basically the “pharma buffet.”
The company’s marketing muscle comes from its massive field force — 2,671 reps — a small army that ensures your friendly neighborhood doctor has a Corona sample pack on their desk.
Manufacturing happens in Gujarat — because where else do you mix chemistry and commerce so efficiently? Both plants are GMP-compliant, focused on high-quality output, and blessed by the R&D gods who ensure they don’t just make copy-paste generics but differentiated products.
They’ve built what they call “engine brands” — long-running cash cows in targeted therapy areas. Think of it as the “Karan Johar of pharma” — once they launch a brand, it sticks around for sequels.
4. Financials Overview
All figures in ₹ crore
Source table
Metric
Q1 FY26 (Jun 2025)
Q1 FY25 (Jun 2024)
Q4 FY25 (Mar 2025)
YoY %
QoQ %
Revenue
348.56
295.40
310.00
18.0%
12.4%
EBITDA
71.80
60.50
65.00
18.7%
10.5%
PAT
46.20
34.00
38.50
35.9%
20.0%
EPS (₹)
7.56
5.57
6.30
35.7%
20.0%
Annualised EPS = ₹7.56 × 4 = ₹30.24
At the upper IPO price of ₹1062, the P/E works out to 35.1x, roughly matching what’s stated in the RHP. That’s in line with mid-size pharma valuations — not cheap, but not as crazy as hospitals pretending to be tech startups.
Commentary: Corona’s growth is consistent, not flashy. Revenue up 18%, PAT up 65% YoY, and low debt make it one of the cleaner pharma financials out there. Their ROE and ROCE suggest efficient capital use, and the expanding EBITDA margin shows operational leverage kicking in — or maybe they just finally stopped
